RESUMO Objetivo: Visto que partículas são liberadas nas seringas durante as injeções intravítreas (IVIs), estas foram avaliadas quantitativamente após a agitação das seringas mais comumente usadas para injeções intravítreas. Métodos: A seringa SR de 1 ml de insulina, a agulha curta Becton-Dickinson Ultra-Fine 0,3 ml com escala de meia unidade, HSW Norm-Ject Tuberculin e a Becton-Dickinson Luer Lok Tip de 1 ml foram estudadas com placedo e com bevacizumabe, aflibercept e ziv-aflibercept, com e sem agitação. MicroFlow Imaging Microscopy foi realizada para avaliar o número de partículas, concentração, morfologia e distribuição das mesmas por tamanho. Resultados: A contagem média de partículas após agitação foi maior do que no grupo sem agitação usando a seringa Becton-Dickinson Ultra-Fine. Diferenças foram observadas usando a seringa SR entre as duas condições estudadas para partículas maiores que 10 e 25 µm. Para as demais seringas, não foram observadas diferenças significativas nas médias. A seringa SR apresentou o maior número de partículas sem agitação (2.417.361,7 ± 3.421.575,5) seguida da Becton-Dickinson Ultra-Fine com 812.530,9 ± 996.187,2. A BD Luer Lok Tip e a HSW Norm-Ject se comportaram de forma semelhante com 398.396,8 ± 484.239,2 e 416.016,4 ± 242.650,1 partículas, respectivamente. Conclusões: Agitar seringas para remover bolhas de ar resulta em um maior número de partículas liberadas durante Becton-Dickinson no vítreo humano. Objetivo IVIs, IVIs , (IVIs) Métodos insulina BectonDickinson Becton Dickinson UltraFine Ultra Fine 03 0 3 0, unidade NormJect Norm Ject bevacizumabe zivaflibercept, zivaflibercept ziv aflibercept, ziv-aflibercept concentração tamanho Resultados UltraFine. Fine. 2 µm médias 2.417.361,7 24173617 417 361 7 (2.417.361, 3.421.575,5 34215755 421 575 5 8125309 812 530 9 812.530, 9961872 996 187 996.187,2 3983968 398 396 8 398.396, 4842392 484 239 484.239, 4160164 416 016 4 416.016, 2426501 242 650 242.650, respectivamente Conclusões humano (IVIs 2.417.361, 2417361 41 36 (2.417.361 3.421.575, 3421575 42 57 812530 81 53 812.530 996187 99 18 996.187, 398396 39 398.396 484239 48 23 484.239 416016 01 416.016 242650 24 65 242.650 2.417.361 241736 (2.417.36 3.421.575 342157 81253 812.53 99618 996.187 39839 398.39 48423 484.23 41601 416.01 24265 6 242.65 2.417.36 24173 (2.417.3 3.421.57 34215 8125 812.5 9961 996.18 3983 398.3 4842 484.2 4160 416.0 2426 242.6 2.417.3 2417 (2.417. 3.421.5 3421 812. 996.1 398. 484. 416. 242. 2.417. 241 (2.417 3.421. 342 996. 2.417 (2.41 3.421 34 2.41 (2.4 3.42 2.4 (2. 3.4 2. (2 3. (
ABSTRACT Purpose: Since particles are released in syringes during intravitreal injections, we assessed them quantitatively after agitating syringes commonly used for intravitreal injections. Methods: With and without agitation, the SR 1-ml insulin, Becton-Dickinson Ultra-Fine 0.3-ml Short Needle with a half-unit scale, HSW Norm-Ject Tuberculin, and Becton-Dickinson 1-ml Luer Lok Tip were examined with buffer and bevacizumab, aflibercept, and ziv-aflibercept. Flow imaging microscopy was performed to assess the particle numbers, concentrations, morphology, and size distribution. Results: Using the Becton-Dickinson Ultra-Fine syringe, the average particle count after agitation was higher than in the no-agitation group. For particles greater than 10 and 25 µm, differences were observed using the SR syringe between the two studied conditions. There were no significant differences in the means for the other syringes. Without agitation, the SR syringe had the highest number of particles (2,417,361.7 ± 3,421,575.5) followed by the Becton-Dickinson Ultra-Fine with 812.530,9 ± 996.187,2. The Becton-Dickinson Luer Lok Tip and HSW Norm-Ject performed equally with 398,396.8 ± 484,239.2 and 416,016.4 ± 242,650.1 particles, respectively. Conclusions: Flicking syringes to eliminate air bubbles results in increased numbers of particles released during intravitreal injections into the human vitreous. Purpose Methods 1ml ml 1 insulin BectonDickinson Becton Dickinson UltraFine Ultra Fine 0.3ml 03ml 0.3 0 3 halfunit half unit scale NormJect Norm Ject Tuberculin bevacizumab aflibercept zivaflibercept. zivaflibercept ziv aflibercept. ziv-aflibercept concentrations morphology distribution Results noagitation group 2 µm conditions 2,417,361.7 24173617 417 361 7 (2,417,361. 3,421,575.5 34215755 421 575 5 8125309 812 530 9 812.530, 9961872 996 187 996.187,2 3983968 398 396 8 398,396. 4842392 484 239 484,239. 4160164 416 016 4 416,016. 2426501 242 650 242,650. respectively Conclusions vitreous 3ml 03 0. 2,417,361. 2417361 41 36 (2,417,361 3,421,575. 3421575 42 57 812530 81 53 812.530 996187 99 18 996.187, 398396 39 398,396 484239 48 23 484,239 416016 01 416,016 242650 24 65 242,650 2,417,361 241736 (2,417,36 3,421,575 342157 81253 812.53 99618 996.187 39839 398,39 48423 484,23 41601 416,01 24265 6 242,65 2,417,36 24173 (2,417,3 3,421,57 34215 8125 812.5 9961 996.18 3983 398,3 4842 484,2 4160 416,0 2426 242,6 2,417,3 2417 (2,417, 3,421,5 3421 812. 996.1 398, 484, 416, 242, 2,417, 241 (2,417 3,421, 342 996. 2,417 (2,41 3,421 34 2,41 (2,4 3,42 2,4 (2, 3,4 2, (2 3, (